P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

• Jayastu Senapati,
• Hagop Kantarjian,
• Alexandre Bazinet,
• Patrick Reville,
• Gautam Borthakur,
• Naval Daver,
• Courtney Dinardo,
• Alex Bataller,
• Elias Jabbour,
• Nicholas Short,
• Uday R. Popat,
• Amin Majid Alousi,
• Elizabeth J. Shpall,
• Guillermo Garcia-Manero,
• Farhad Ravandi,
• Tapan Kadia

Affiliations

Jayastu Senapati

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Alexandre Bazinet

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Patrick Reville

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Gautam Borthakur

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Naval Daver

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Courtney Dinardo

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Alex Bataller

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Elias Jabbour

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Uday R. Popat

2 The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation, Houston, United States

Amin Majid Alousi

2 The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation, Houston, United States

Elizabeth J. Shpall

2 The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation, Houston, United States

Guillermo Garcia-Manero

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Tapan Kadia

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States